Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Pia Clara Pafundi, Antonio Parrella, Domenico Iossa, Rosa Molaro, Carminia Battimelli, Erasmo Falco, Giuseppe Sodano, Riccardo Utili & Emanuele Durante-Mangoni. (2017) Viability of pegIFNα-RBV for CHC in the direct acting antiviral era: a practical algorithm between efficacy and cost containment. Journal of Chemotherapy 29:2, pages 94-101.
Read now
Read now
Elisabetta Degasperi, Mauro Viganò, Alessio Aghemo, Pietro Lampertico & Massimo Colombo. (2013) PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history. Expert Review of Anti-infective Therapy 11:5, pages 459-474.
Read now
Read now
José M. Ladero, Gustavo López-Alonso, María J. Devesa, Francisca Cuenca, Marta Ágreda, Luis Ortega, Avelina Suárez & Manuel Díaz-Rubio. (2008) “12 weeks’ stopping rule” in the treatment of genotype 1 chronic hepatitis C: Two prognostic categories under the same label?. Scandinavian Journal of Gastroenterology 43:8, pages 979-983.
Read now
Read now
Articles from other publishers (38)
Dezhi Wei & Miao Ge. (2018) The spatial distribution of BUN reference values of Chinese healthy adults: a cross-section study. International Journal of Biometeorology 62:12, pages 2099-2107.
Crossref
Crossref
Tania M Welzel, K Rajender Reddy, Steven L Flamm, Jill Denning, Ming Lin, Rob Hyland, Phillip S Pang, John G McHutchison, Michael Charlton, Gregory T Everson, Stefan Zeuzem & Nezam Afdhal. (2015) On-Treatment HCV RNA in Patients with Varying Degrees of Fibrosis and Cirrhosis in the SOLAR-1 Trial. Antiviral Therapy 21:6, pages 541-546.
Crossref
Crossref
Elisabetta Degasperi & Alessio Aghemo. (2015) Genotype 2 Patients: What is the Optimum Therapy so Far?. Current Hepatology Reports 14:4, pages 253-259.
Crossref
Crossref
Thomas Berg, Pietro Andreone, Stanislas Pol, Stuart Roberts, Zobair Younossi, Moises Diago, Eric J. Lawitz, Roberto Focaccia, Graham R. Foster, Andrzej Horban, Isabelle Lonjon-Domanec, Ralph DeMasi, Gaston Picchio, Donghan Luo, Sandra De Meyer & Stefan Zeuzem. (2015) Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study. Liver International 35:2, pages 448-454.
Crossref
Crossref
Jhon Edison Prieto Ortíz, Santiago Sánchez Pardo, Ever Leonardo Rojas Díaz & Sandra Judith Huertas Pacheco. (2014) Hepatitis C crónica: aspectos clínicos, serológicos y de tratamiento en dos centros de atención en Bogotá, Colombia. Revista Colombiana de Gastroenterología 29:4, pages 424-432.
Crossref
Crossref
Vadim Brjalin, Riina Salupere, Tatjana Tallo, Tatiana Kuznetsova, Ljudmilla Priimägi & Valentina Tefanova. (2013) Predictors of treatment response in patients with hepatitis C 1b genotype. Open Medicine 8:6, pages 822-829.
Crossref
Crossref
Viola Knop, Gerlinde Teuber, Hartwig Klinker, Bernd Möller, Jens Rasenack, Holger Hinrichsen, Tilman Gerlach, Ulrich Spengler, Peter Buggisch, Konrad Neumann, Christoph Sarrazin, Stefan Zeuzem & Thomas Berg. (2013) Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. Annals of Hepatology 12:2, pages 190-198.
Crossref
Crossref
Muchandidemba Marufu, Hugh Williams, Samuel L Hill, Jeremy Tibble & Sumita Verma. (2012) Gender differences in hepatitis C seroprevalence and suboptimal vaccination and hepatology services uptake amongst substance misusers. Journal of Medical Virology 84:11, pages 1737-1743.
Crossref
Crossref
A. V. Marangon, R. A. Moliterno, A. M. Sell, C. F. V. de Moraes, R. M. T. Grotto, M. C. Pardini, D. S. De Pauli, J. E. L. Visentainer & G. F. Silva. (2012) Influence of HLA alleles in response to treatment with pegylated interferon‐alpha and ribavirin in patients with chronic hepatitis C. International Journal of Immunogenetics 39:4, pages 296-302.
Crossref
Crossref
Vadim Brjalin, Riina Salupere, Tatjana Tallo, Tatiana Kuznetsova, Ljudmilla Priimägi & Valentina Tefanova. (2012) Efficacy of Peginterferon alfa-2a and Ribavirin Combination Therapy in Treatment-naive Estonian Patients with Chronic Hepatitis C. Central European Journal of Public Health 20:2, pages 150-155.
Crossref
Crossref
Jian-Wu Yu, Li-Jie Sun, Peng Kang, Bing-Zhu Yan & Yong-Hua Zhao. (2012) Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C. Hepatobiliary & Pancreatic Diseases International 11:2, pages 185-192.
Crossref
Crossref
E. Degasperi & A. Aghemo. (2012) Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C. Journal of Viral Hepatitis 19:s1, pages 3-6.
Crossref
Crossref
Nanna Hansen, Niels Obel, Peer B Christensen, Mette Kjær, Alex L Laursen, Henrik B Krarup, Axel Møller, Poul Schlichting, Jens Bukh & Nina Weis. (2011) Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study. BMC Infectious Diseases 11:1.
Crossref
Crossref
Viola Weich, Eva Herrmann, Tje Lin Chung, Christoph Sarrazin, Holger Hinrichsen, Peter Buggisch, Tilman Gerlach, Hartwig Klinker, Ulrich Spengler, Alexandra Bergk, Stefan Zeuzem & Thomas Berg. (2011) The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. Journal of Gastroenterology 46:12, pages 1427-1436.
Crossref
Crossref
S. K. Tohra, S. Taneja, S. Ghosh, B. K. Sharma, A. Duseja, R. K. Dhiman, A. Das & Y. K. Chawla. (2011) Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C. Digestive Diseases and Sciences 56:8, pages 2449-2455.
Crossref
Crossref
Michael W. Fried, Stephanos J. Hadziyannis, Mitchell L. Shiffman, Diethelm Messinger & Stefan Zeuzem. (2011) Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. Journal of Hepatology 55:1, pages 69-75.
Crossref
Crossref
Hugo R. Rosen. (2011) Chronic Hepatitis C Infection. New England Journal of Medicine 364:25, pages 2429-2438.
Crossref
Crossref
Hiroaki Ikezaki, Norihiro Furusyo, Takeshi Ihara, Takeo Hayashi, Eiichi Ogawa, Kazuhiro Toyoda, Hiroaki Taniai, Mosaburo Kainuma, Masayuki Murata & Jun Hayashi. (2011) Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C. Journal of Infection and Chemotherapy 17:6, pages 737-743.
Crossref
Crossref
Andreas Maieron, Sigrid Metz-Gercek, Franz Hackl, Alexander Ziachehabi, Harri Fuchsteiner, Christoph Luger, Helmut Mittermayer & Rainer Schöfl. (2010) Antiviral treatment of chronic hepatitis C in clinical routineHepatitis C Therapie: Ergebnisse in der klinischen Routine. Wiener klinische Wochenschrift 122:7-8, pages 237-242.
Crossref
Crossref
Olav Dalgard. 2010. Clinical Dilemmas in Viral Liver Disease. Clinical Dilemmas in Viral Liver Disease
73
75
.
G Brook, J Main, M Nelson, S Bhagani, E Wilkins, C Leen, M Fisher, Y Gilleece, R Gilson, A Freedman, R Kulasegaram, K Agarwal, C Sabin & C Deacon‐Adams. (2009) British HIV Association guidelines for the management of coinfection with HIV‐1 and hepatitis B or C virus 2010. HIV Medicine 11:1, pages 1-30.
Crossref
Crossref
Ezequiel Ridruejo, Raúl Adrover, Daniel Cocozzella, Nora Fernández & María Virginia Reggiardo. (2010) Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon – Ribavirin in daily practice. Annals of Hepatology 9:1, pages 46-51.
Crossref
Crossref
J. ROY ROBERTSON. (2009)
Commentary on Senn
et al.
(2009): Primary care is the place to manage hepatitis C in opiate‐dependent patients
. Addiction 104:12, pages 2039-2040.
Crossref
Crossref
K. R. Reddy, D. Messinger, M. Popescu & S. J. Hadziyannis. (2009) Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. Journal of Viral Hepatitis 16:10, pages 724-731.
Crossref
Crossref
J. J. WEISS, N. BRÄU, A. STIVALA, T. SWAN & D. FISHBEIN. (2009) Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. Alimentary Pharmacology & Therapeutics 30:1, pages 14-27.
Crossref
Crossref
Rosa Quelhas & Alice Lopes. (2009) Psychiatric Problems in Patients Infected with Hepatitis C Before and During Antiviral Treatment with Interferon-Alpha: A Review. Journal of Psychiatric Practice 15:4, pages 262-281.
Crossref
Crossref
Chun-che Lin & Mei-chin Yin. (2009) Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alfa and ribavirin. Clinical Nutrition 28:1, pages 34-38.
Crossref
Crossref
Maribel Rodriguez-Torres, Lennox J. Jeffers, Muhammad Y. Sheikh, Lorenzo Rossaro, Victor Ankoma-Sey, Fayez M. Hamzeh & Paul Martin. (2009) Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C. New England Journal of Medicine 360:3, pages 257-267.
Crossref
Crossref
Susan J. Keam & Risto S. Cvetković. (2009) Spotlight on Peginterferon-α-2a (40 kD) Plus Ribavirin in the Management of Chronic Hepatitis C Mono-Infection†. BioDrugs 23:1, pages 63-68.
Crossref
Crossref
P. Ferenci. (2008) Peginterferon and ribavirin in HCV: Improvement of sustained viral response. Best Practice & Research Clinical Gastroenterology 22:6, pages 1109-1122.
Crossref
Crossref
Richard Njouom, Michèle Tagni Sartre, Isabelle Timba, Eric Nerrienet, Patrice Tchendjou, Christophe Pasquier & Dominique Rousset. (2008) Efficacy and safety of peginterferon alpha‐2a/ribavirin in treatment‐naive Cameroonian patients with chronic hepatitis C. Journal of Medical Virology 80:12, pages 2079-2085.
Crossref
Crossref
Moisés Diago. (2008) Tratamiento de la infección por el virus de la hepatitis C. Estado actual y perspectivas. Gastroenterología y Hepatología 31:9, pages 596-605.
Crossref
Crossref
Michael W. Fried, Donald M. Jensen, Maribel Rodriguez-Torres, Lisa M. Nyberg, Adrian M. Di Bisceglie, Timothy R. Morgan, Paul J. Pockros, Amy Lin, Lisa Cupelli, Frank Duff, Ka Wang & David R. Nelson. (2008) Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon α-2a and ribavirin. Hepatology 48:4, pages 1033-1043.
Crossref
Crossref
GRAHAM R. FOSTER. (2008) Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy?. Addiction 103:9, pages 1412-1413.
Crossref
Crossref
Eric Lawitz, Maribel Rodriguez-Torres, Andrew J. Muir, Tara L. Kieffer, Lindsay McNair, Ariya Khunvichai & John G. McHutchison. (2008) Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. Journal of Hepatology 49:2, pages 163-169.
Crossref
Crossref
B. J. Thomson, G. Kwong, S. Ratib, M. Sweeting, S. D. Ryder, D. De Angelis, R. Grieve & W. L. Irving. (2008) Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management. Journal of Viral Hepatitis 15:4, pages 271-278.
Crossref
Crossref
Bader Faiyaz Zuberi, Faisal Faiyaz Zuberi, Sajjad Ali Memon, Muhammad Hafeez Qureshi, Sheikh Zafar Ali & Salahuddin Afsar. (2008) Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population. World Journal of Gastroenterology 14:14, pages 2218.
Crossref
Crossref
Susan J Keam & Risto S Cvetković. (2008) Peginterferon-α-2a (40 kD) Plus Ribavirin. Drugs 68:9, pages 1273-1317.
Crossref
Crossref